Novo Nordisk Reports Q3 Sales Growth, Raises 2026 Guidance
Sales rose 6% to 79.19 billion Danish kroner. Novo Nordisk raised its full-year sales and adjusted operating profit growth outlook to -2% to 2% at constant exchange rates, an improvement of approximately three percentage points over its previous expectations. Wegovy pill sales were 5.39 billion kroner.
Story updates
Novo Nordisk announced its third-quarter 2026 financial results, reporting a 6% increase in sales to 79.19 billion Danish kroner. Driven by strong uptake of its GLP-1 products, including the recently launched Wegovy pill, the company raised its 2026 full-year guidance for both sales and adjusted operating profit growth to a range of -2% to 2% at constant exchange rates. This updated outlook represents an improvement of approximately three percentage points over previous expectations. The company noted that the Wegovy pill contributed 5.39 billion kroner in sales during the quarter.